Apellis Pharmaceuticals, Inc

(NASDAQ:APLS)

Latest On Apellis Pharmaceuticals, Inc (APLS):

Date/Time Type Description Signal Details
2023-05-25 17:48 ESTNewsApellis and Sobi to drop ALS candidate on Phase 2 setbackN/A
2023-05-18 17:01 ESTNewsApellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition SpaceN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.56 misses by $0.10, revenue of $44.84M beats by $18.74MN/A
2023-05-03 20:58 ESTNewsApellis Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-05-01 19:14 ESTNewsApellis weakness on Iveric Bio takeout is buying opportunity - analystN/A
2023-05-01 06:55 ESTNewsApellis Pharmaceuticals (APLS) Presents at the Association for Research in Vision and Ophthalmology Annual Meeting - SlideshowN/A
2023-04-03 17:26 ESTNewsApellis Pharmaceuticals may be worth $90-$100 a share in sale - analystN/A
2023-04-02 23:22 ESTNewsApellis Pharmaceuticals sees takeover interest from large pharma - BloombergN/A
2023-03-24 22:48 ESTNewsApellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy MarketN/A
2023-03-16 14:19 ESTNewsApellis Pharmaceuticals' Empaveli sNDA action date extended by FDAN/A
2023-02-23 11:44 ESTNewsApellis Pharmaceuticals prices $350M in stock offeringN/A
2023-02-22 09:58 ESTNewsApellis Pharmaceuticals to raise $300M in stock and warrants offeringN/A
2023-02-21 21:29 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.50 beats by $0.06, revenue of $22.66M misses by $1.86MN/A
2023-02-18 02:43 ESTNewsApellis wins FDA nod for eye disorder therapyN/A
2023-01-27 18:43 ESTNewsApellis: Empaveli Ought To Win Approval For Eye Disease In February - The Future Looks BrightN/A
2023-01-21 14:26 ESTNewsStocks To Watch: Earnings Heat Up, Healthcare Catalysts And M&A WildcardsN/A
2023-01-05 20:02 ESTNewsApellis appoints Baumal as Chief Medical OfficerN/A
2023-01-04 02:30 ESTNewsApellis, Arvinas lower as Wells Fargo downgrades in 2023 biotech previewN/A
2022-12-15 23:44 ESTNewsApellis Pharmaceuticals: Approval Is Baked Into ValuationN/A
2022-11-18 10:24 ESTNewsApellis surges 17% as FDA accepts to review new data in filing for eye disorder drugN/A
2022-11-11 06:07 ESTNewsApellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA marketN/A
2022-11-08 08:01 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.75 misses by $0.29, revenue of $22.05M beats by $0.46MN/A
2022-11-08 08:00 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q3 2022 Earnings Call TranscriptN/A
2022-11-05 08:22 ESTNewsApellis Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-11-03 23:08 ESTNewsApellis sinks 20% as FDA review period for eye disease drug extendsN/A
2022-10-16 23:00 ESTNewsCiti lists four more value-creating events in biotech for this yearN/A
2022-09-29 06:33 ESTNewsApellis Pharmaceuticals: Trying To Develop A Blockbuster FranchiseN/A
2022-09-08 07:22 ESTNewsApellis gains as FDA says AdCom unnecessary for eye disease candidateN/A
2022-08-24 16:51 ESTNewsApellis stock dips amid 2-year data of pegcetacoplan for eye disorderN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 18:56 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.46 misses by $0.09, revenue of $16.32M misses by $0.63MN/A
2022-08-06 06:05 ESTNewsApellis Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-27 15:50 ESTNewsApellis to exchange $75.6M in convertible senior notes for common stockN/A
2022-07-20 18:36 ESTNewsApellis Pharmaceuticals: The Meaning Of Priority Review For Pegcetacoplan For Geographic AtrophyN/A
2022-07-20 03:57 ESTNewsWainwright sees blockbuster potential for Apellis eye degeneration therapy; shares up 22%N/A
2022-07-19 13:21 ESTNewsApellis stock soars 24% as FDA grants priority review to pegcetacoplan for eye disorderN/A
2022-07-19 13:19 ESTNewsH.C. Wainwright sees blockbuster potential for Apellis' treatment in eye degenerationN/A
2022-06-25 15:25 ESTNewsApellis: Mixed Data, But Definitely Approvable In GAN/A
2022-06-13 19:55 ESTNewsHot Stocks: APLS & SKIL both gain, TSLA declined despite upgrade, and VLTA plungedN/A
2022-06-10 11:34 ESTNewsApellis/Sobi Empaveli shows benefit in rare blood disorder patients in new analysesN/A
2022-06-01 11:05 ESTNewsApellis files for FDA approval of pegcetacoplan to treat eye disorderN/A
2022-05-06 19:17 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-06 19:15 ESTNewsApellis Pharmaceuticals (APLS) Investor Presentation - SlideshowN/A
2022-05-04 22:43 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.42 misses by $0.12, revenue of $12.1M misses by $0.52MN/A
2022-05-04 22:42 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 03:15 ESTNewsApellis Pharmaceuticals Q1 2022 Earnings PreviewN/A

About Apellis Pharmaceuticals, Inc (APLS):

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Apellis Pharmaceuticals, Inc
  • Symbol APLS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 374
  • Fiscal Year EndDecember
  • IPO Date2017-11-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.apellis.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 13.99
  • Price/Book (Most Recent Quarter) 18.33
  • Enterprise Value Revenue 12.97
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$6.46
  • Next Year EPS Estimate -$5.31
  • Next Quarter EPS Estimate -$1.60
  • Profit Margin -138%
  • Operating Margin -85%
  • Return on Assets -20%
  • Return on Equity -289%
  • Revenue 250.65 million
  • Earnings Per Share -$3.32
  • Revenue Per Share $3.34
  • Gross Profit -74325000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 3.54 billion
  • Analyst Target Price $64.14
  • Book Value Per Share $2.69
View More

Share Statistics

  • Shares Outstanding 80.38 million
  • Shares Float 59.7 million
  • % Held by Insiders 2117%
  • % Held by Institutions 82.85%
  • Shares Short 8.11 million
  • Shares Short Prior Month 7.75 million
  • Short Ratio 13.44
  • Short % of Float 15%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.52
  • 52 Week High $58.47
  • 52 Week Low $21.84
  • 50 Day Moving Average 46.47
  • 200 Day Moving Average 42.62
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Apellis Pharmaceuticals, Inc (APLS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Apellis Pharmaceuticals, Inc (APLS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A$0.93-$0.45304.58%
2020-09-302020-11-02$646000-$1.79-$1.58-13.31%
2020-06-302020-07-30$N/A-$1.57-$1.34-17.56%
2020-03-312020-04-29$N/A-$2.29-$1.39-64.72%
2019-12-312020-02-27$N/A-$1.77-$1.14-55%
2019-09-302019-11-05$N/A-$1.10-$1.03-6.44%
2019-06-302019-07-31$N/A-$1.12-$0.78-44.39%
2019-03-312019-05-07$N/A-$0.87-$0.68-27.49%
2018-12-312019-02-26$N/A-$0.65-$0.707.58%
2018-09-302018-11-13$N/A-$0.64-$0.697.02%
2018-06-302018-07-31$N/A-$0.61-$0.42-45.86%
2018-03-312018-04-30$N/A-$0.43-$0.27-57.28%
2017-12-312018-03-19$N/A-$0.61-$0.27-129.32%
2017-09-302017-12-20$N/A-$0.23-$0.242.75%

Apellis Pharmaceuticals, Inc (APLS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Apellis Pharmaceuticals, Inc (APLS) Chart:

Apellis Pharmaceuticals, Inc (APLS) News:

Below you will find a list of latest news for Apellis Pharmaceuticals, Inc (APLS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Apellis Pharmaceuticals, Inc (APLS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-19110CALL0 0463.5TRUE00
2025-09-19120CALL0 0426.58TRUE00
2025-09-19130CALL0 0357.13TRUE00
2025-09-19140CALL0 0329.02TRUE00
2025-09-19155.12CALL0 1303.03TRUE00
2025-09-191611.8CALL0 12315.78TRUE00
2025-09-19170CALL0 0256.12TRUE00
2025-09-191810CALL0 201114.4TRUE00
2025-09-19193.8CALL0 7109.32TRUE00
2025-09-19208.47CALL0 42142.35TRUE00
2025-09-19215.5CALL0 5070.72TRUE00
2025-09-19225.57CALL0 47105.25TRUE00
2025-09-19235.09CALL0 5150.28TRUE00
2025-09-19243.9CALL1 7458.27TRUE3.90
2025-09-19253.5CALL0 47346.19TRUE00
2025-09-19262.9CALL0 58246.29TRUE00
2025-09-19271.45CALL7 16443.41TRUE1.450
2025-09-19280.93CALL10 23446.25FALSE-0.62-0.4
2025-09-19290.67CALL2 107946.77FALSE0.670
2025-09-19300.4CALL70 4546.16FALSE0.40
2025-09-19310.37CALL0 22140.39FALSE00
2025-09-19320.11CALL1 2244.37FALSE-0.11-0.5
2025-09-19330.5CALL0 255.08FALSE00
2025-09-19340.1CALL0 549.15FALSE00
2025-09-19350.08CALL0 168.03FALSE00
2025-09-19360CALL0 083.56FALSE00
2025-09-19110PUT0 0261.78FALSE00
2025-09-19120PUT0 0239.76FALSE00
2025-09-19130PUT0 0219.58FALSE00
2025-09-19140PUT0 0215.78FALSE00
2025-09-19150.44PUT0 1183.53FALSE00
2025-09-19160.15PUT0 11167.22FALSE00
2025-09-19170.15PUT0 4154.98FALSE00
2025-09-19180.25PUT0 47137.24FALSE00
2025-09-19190.05PUT0 8126FALSE00
2025-09-19200.2PUT0 1784.64FALSE00
2025-09-19211.05PUT0 1199.32FALSE00
2025-09-19220.32PUT0 19388.62FALSE00
2025-09-19230.4PUT0 16559.13FALSE00
2025-09-19240.45PUT0 3648.47FALSE00
2025-09-19250.8PUT0 42346.4FALSE00
2025-09-19260.55PUT3 43047.68FALSE0.130.31
2025-09-19270.85PUT2 101744.65FALSE0.850
2025-09-19281.35PUT1 30244.53TRUE0.150.13
2025-09-19291.93PUT0 1047.2TRUE00
2025-09-19300PUT0 047.57TRUE00
2025-09-19310PUT0 045.61TRUE00
2025-09-19320PUT0 049.81TRUE00
2025-09-19330PUT0 077.94TRUE00
2025-09-19340PUT0 085.94TRUE00
2025-09-19350PUT0 096.58TRUE00
2025-09-19360PUT0 076.57TRUE00
2025-10-17109.08CALL0 5309.77TRUE00
2025-10-171111.05CALL0 60304.23TRUE00
2025-10-17120CALL0 0279.87TRUE00
2025-10-171310.22CALL0 2257.87TRUE00
2025-10-17148CALL0 4237.81TRUE00
2025-10-17158.39CALL0 1093.2TRUE00
2025-10-171611.89CALL0 291.12TRUE00
2025-10-17175.9CALL0 1274.57TRUE00
2025-10-17189.03CALL0 34355.4TRUE00
2025-10-17199.49CALL0 18647.39TRUE00
2025-10-17207CALL0 158961.37TRUE00
2025-10-17216.4CALL0 17549.01TRUE00
2025-10-17226.64CALL0 5155.28TRUE00
2025-10-17235.46CALL0 7451.84TRUE00
2025-10-17244.5CALL0 13951.09TRUE00
2025-10-17253.95CALL0 364346.79TRUE00
2025-10-17263.05CALL0 8049.71TRUE00
2025-10-17272.45CALL0 31347.41TRUE00
2025-10-17282.25CALL0 12948.23FALSE00
2025-10-17291.55CALL0 33447.63FALSE00
2025-10-17301.05CALL102 37847.68FALSE1.050
2025-10-17310.8CALL4 10548.01FALSE-0.15-0.16
2025-10-17320.57CALL2 2847.2FALSE0.570
2025-10-17330.6CALL0 5747.59FALSE00
2025-10-17340CALL0 042.29FALSE00
2025-10-17350.26CALL4 746.53FALSE-0.09-0.26
2025-10-17360CALL0 545.45FALSE00
2025-10-17400CALL0 2658.97FALSE00
2025-10-17100PUT0 0185.15FALSE00
2025-10-17110PUT0 0169.5FALSE00
2025-10-17120.55PUT0 96166.43FALSE00
2025-10-17130PUT0 17142.26FALSE00
2025-10-17140.8PUT0 112139.84FALSE00
2025-10-17150.05PUT0 563123.62FALSE00
2025-10-17161PUT0 5112.77FALSE00
2025-10-17170.05PUT0 13102.54FALSE00
2025-10-17180.15PUT0 40394.6FALSE00
2025-10-17190.21PUT0 26985.21FALSE00
2025-10-17200.5PUT0 42760.12FALSE00
2025-10-17210.6PUT0 14956.63FALSE00
2025-10-17220.25PUT0 11150.73FALSE00
2025-10-17230.58PUT0 2955.22FALSE00
2025-10-17240.83PUT0 752.24FALSE00
2025-10-17250.75PUT0 64049.51FALSE00
2025-10-17261.22PUT0 1346.65FALSE00
2025-10-17271.8PUT0 547.87FALSE00
2025-10-17282.15PUT3 12049.98TRUE2.150
2025-10-17290PUT0 047.52TRUE00
2025-10-17300PUT0 048.22TRUE00
2025-10-17315.1PUT0 147.05TRUE00
2025-10-17320PUT0 046.97TRUE00
2025-10-17330PUT0 048.92TRUE00
2025-10-17340PUT0 049.7TRUE00
2025-10-17350PUT0 058.99TRUE00
2025-10-17360PUT0 058.85TRUE00
2025-10-17400PUT0 068.33TRUE00
2026-01-16100CALL0 0174.65TRUE00
2026-01-16110CALL0 049.84TRUE00
2026-01-16120CALL0 083.18TRUE00
2026-01-16130CALL0 878.9TRUE00
2026-01-16140CALL0 071.04TRUE00
2026-01-16158.5CALL0 4059.83TRUE00
2026-01-16165CALL0 268.36TRUE00
2026-01-161710.09CALL0 5965.88TRUE00
2026-01-161811.6CALL0 14269.72TRUE00
2026-01-161910.15CALL0 2880.47TRUE00
2026-01-16208.86CALL6 1004163.32TRUE8.860
2026-01-16217.85CALL0 12859.98TRUE00
2026-01-1622.56.31CALL0 9361.37TRUE00
2026-01-16245.95CALL0 10058.97TRUE00
2026-01-16255.5CALL1 205560.06TRUE5.50
2026-01-16263.3CALL0 3557.98TRUE00
2026-01-16274.31CALL0 2860.02TRUE00
2026-01-16280CALL0 051.26FALSE00
2026-01-16293.9CALL0 23756.94FALSE00
2026-01-16303.4CALL0 151552.41FALSE00
2026-01-16313.8CALL0 10153.98FALSE00
2026-01-16322.7CALL0 3858.84FALSE00
2026-01-16332.7CALL0 1658.81FALSE00
2026-01-16342.45CALL0 30656.79FALSE00
2026-01-16351.76CALL6 168157.65FALSE-0.24-0.12
2026-01-16400.86CALL152 1055555.41FALSE0.860
2026-01-16450.8CALL0 47050.41FALSE00
2026-01-16500.28CALL0 36762.16FALSE00
2026-01-16550.37CALL0 39073.67FALSE00
2026-01-16600.05CALL0 118261.4FALSE00
2026-01-16650.15CALL0 40096.11FALSE00
2026-01-16700CALL0 34873FALSE00
2026-01-16750.05CALL0 5586.54FALSE00
2026-01-16800CALL0 18676.62FALSE00
2026-01-16850CALL0 63795.93FALSE00
2026-01-16900CALL0 8499.58FALSE00
2026-01-16950CALL0 2497.05FALSE00
2026-01-161000CALL0 27106.18FALSE00
2026-01-161050CALL0 96107.78FALSE00
2026-01-16100PUT0 12115.61FALSE00
2026-01-16110PUT0 096.54FALSE00
2026-01-16120.12PUT5 576.39FALSE0.120
2026-01-16130PUT0 10082.84FALSE00
2026-01-16140.5PUT0 689.44FALSE00
2026-01-16151.5PUT0 12170.85FALSE00
2026-01-16160PUT0 079.08FALSE00
2026-01-16170.5PUT0 8170.44FALSE00
2026-01-16181.25PUT0 20358.58FALSE00
2026-01-16191.05PUT0 1761.24FALSE00
2026-01-16200.9PUT2 68561.41FALSE0.90
2026-01-16212.2PUT0 5260.58FALSE00
2026-01-1622.51.93PUT0 23060.3FALSE00
2026-01-16242.17PUT0 5159.67FALSE00
2026-01-16252.3PUT0 28359.24FALSE00
2026-01-16263.2PUT0 3458.97FALSE00
2026-01-16273.84PUT0 458.44FALSE00
2026-01-16286PUT0 33161.08TRUE00
2026-01-16290PUT0 057.52TRUE00
2026-01-16305.1PUT0 125457.89TRUE00
2026-01-16316PUT0 159.23TRUE00
2026-01-16320PUT0 059.35TRUE00
2026-01-16330PUT0 058.24TRUE00
2026-01-16340PUT0 053.31TRUE00
2026-01-16350PUT0 73156.04TRUE00
2026-01-16400PUT0 156.11TRUE00
2026-01-16450PUT0 066.32TRUE00
2026-01-16500PUT0 1293.62TRUE00
2026-01-16550PUT0 2384.79TRUE00
2026-01-16600PUT0 089.24TRUE00
2026-01-16650PUT0 337102.53TRUE00
2026-01-16700PUT0 116390.81TRUE00
2026-01-16750PUT0 0108.31TRUE00
2026-01-16800PUT0 0115.56TRUE00
2026-01-16850PUT0 0116.91TRUE00
2026-01-16900PUT0 0123.62TRUE00
2026-01-16950PUT0 0126.13TRUE00
2026-01-161000PUT0 0132.43TRUE00
2026-01-161050PUT0 0129.61TRUE00
2026-04-17150CALL0 067.18TRUE00
2026-04-17160CALL0 066.76TRUE00
2026-04-17170CALL0 065.65TRUE00
2026-04-17180CALL0 064.05TRUE00
2026-04-17190CALL0 064.07TRUE00
2026-04-17200CALL0 061.68TRUE00
2026-04-17210CALL0 062.39TRUE00
2026-04-17220CALL0 058.63TRUE00
2026-04-17230CALL0 060.6TRUE00
2026-04-17240CALL0 059.15TRUE00
2026-04-17250CALL0 056.76TRUE00
2026-04-17260CALL0 056.62TRUE00
2026-04-17276.1CALL0 558.52TRUE00
2026-04-17280CALL0 058.17FALSE00
2026-04-17290CALL0 055.76FALSE00
2026-04-17300CALL0 057.67FALSE00
2026-04-17310CALL0 055.54FALSE00
2026-04-17320CALL0 055.69FALSE00
2026-04-17330CALL0 056.71FALSE00
2026-04-17340CALL0 056.33FALSE00
2026-04-17352.9CALL0 2555.69FALSE00
2026-04-17360CALL0 055.99FALSE00
2026-04-17401.71CALL0 155.12FALSE00
2026-04-17150PUT0 069.43FALSE00
2026-04-17160PUT0 068.65FALSE00
2026-04-17170.81PUT0 264.21FALSE00
2026-04-17181.11PUT0 065.46FALSE00
2026-04-17190PUT0 065.28FALSE00
2026-04-17200PUT0 062.74FALSE00
2026-04-17210PUT0 062.48FALSE00
2026-04-17220PUT0 060.96FALSE00
2026-04-17230PUT0 062.33FALSE00
2026-04-17240PUT0 061.4FALSE00
2026-04-17253.39PUT0 560.44FALSE00
2026-04-17260PUT0 058.83FALSE00
2026-04-17270PUT0 059.04FALSE00
2026-04-17280PUT0 055.33TRUE00
2026-04-17290PUT0 058.93TRUE00
2026-04-17300PUT0 056.94TRUE00
2026-04-17310PUT0 058.09TRUE00
2026-04-17320PUT0 059.53TRUE00
2026-04-17330PUT0 058.96TRUE00
2026-04-17340PUT0 056.92TRUE00
2026-04-17350PUT0 055.13TRUE00
2026-04-17360PUT0 057.35TRUE00
2026-04-17400PUT0 055.96TRUE00
2027-01-15515.1CALL0 485.76TRUE00
2027-01-151013.91CALL0 1864.19TRUE00
2027-01-151514.5CALL0 6958.15TRUE00
2027-01-152011.42CALL0 8947.73TRUE00
2027-01-15234.9CALL0 2854.75TRUE00
2027-01-15259.06CALL0 5348.71TRUE00
2027-01-15287.27CALL0 653.96FALSE00
2027-01-15306.53CALL0 20550.49FALSE00
2027-01-15335.63CALL0 448.92FALSE00
2027-01-15354.65CALL0 281445.99FALSE00
2027-01-15370CALL0 049.16FALSE00
2027-01-15403.6CALL0 25247.34FALSE00
2027-01-15423.6CALL0 270547.36FALSE00
2027-01-15450.85CALL0 3450.39FALSE00
2027-01-15472.43CALL0 149.23FALSE00
2027-01-15501.4CALL0 4045.96FALSE00
2027-01-15551.72CALL0 41346.08FALSE00
2027-01-1550PUT0 0112.13FALSE00
2027-01-15100.7PUT0 168.99FALSE00
2027-01-15151.15PUT0 20259.12FALSE00
2027-01-15204.24PUT0 11563.69FALSE00
2027-01-15230PUT0 254.53FALSE00
2027-01-15254.63PUT0 36551.02FALSE00
2027-01-15286.41PUT0 555.23TRUE00
2027-01-15308.24PUT0 43253.79TRUE00
2027-01-153316.37PUT0 548.78TRUE00
2027-01-153510.21PUT0 48251.04TRUE00
2027-01-15370PUT0 047.48TRUE00
2027-01-15400PUT0 050.01TRUE00
2027-01-15420PUT0 249.72TRUE00
2027-01-15450PUT0 048.77TRUE00
2027-01-15470PUT0 052.97TRUE00
2027-01-15500PUT0 051.12TRUE00
2027-01-15550PUT0 049.73TRUE00

Latest APLS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$39.4
Jun 13, 2022 7:59 PM EST25$39.4
Jun 13, 2022 7:59 PM EST86$39.39
Jun 13, 2022 7:59 PM EST14$39.4
Jun 13, 2022 7:59 PM EST32$39.4

Apellis Pharmaceuticals, Inc (APLS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000083423720004741/0000834237-20-004741-index.htm
2020-02-053/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320003295/0000899243-20-003295-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320008068/0000899243-20-008068-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027595/0000899243-20-027595-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027598/0000899243-20-027598-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090221920000352/0000902219-20-000352-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090266420001196/0000902664-20-001196-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000092963820000336/0000929638-20-000336-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013334/0001127602-20-013334-index.htm
2020-04-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013338/0001127602-20-013338-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-04-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014554/0001127602-20-014554-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-06-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019258/0001127602-20-019258-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052855/0001193125-20-052855-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052867/0001193125-20-052867-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520098977/0001193125-20-098977-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115068/0001193125-20-115068-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115084/0001193125-20-115084-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520135621/0001193125-20-135621-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520141579/0001193125-20-141579-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520157384/0001193125-20-157384-index.htm
2020-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520277496/0001193125-20-277496-index.htm
2010-05-19DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1492242/000149224210000001/0001492242-10-000001-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1492422/000156459020007350/0001564590-20-007350-index.htm
2020-04-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020019689/0001564590-20-019689-index.htm
2020-07-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020034763/0001564590-20-034763-index.htm
2020-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020049423/0001564590-20-049423-index.htm
2020-08-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1492422/999999999720004458/9999999997-20-004458-index.htm

Apellis Pharmaceuticals, Inc (APLS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Apellis Pharmaceuticals, Inc (APLS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2117%
Institutional Ownership: 8285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-13Pascal DeschateletsChief Operating OfficerSell55,398.0040.982,270,154.641,008,681.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell5,000.0040.67203,330.001,027,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell30,637.0040.661,245,792.331,032,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell300.0023.867,158.001,053,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell3,212.0022.2871,556.941,053,367.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell15,065.0021.58325,087.641,056,579.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-02-19Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,058,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,063,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-13Pascal DeschateletsChief Operating OfficerBuy117,205.002.14250,818.701,064,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-10Cedric FrancoisChief Executive OfficerBuy34,375.001,066,805.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell12,060.0020.69249,557.581,071,644.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-10-15Cedric FrancoisChief Executive OfficerSell5,000.0034.46172,300.001,083,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-03-17Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell700.0022.2915,600.201,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,192.0021.5747,279.251,084,404.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,108.0020.7343,694.621,086,596.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-09-15Cedric FrancoisChief Executive OfficerSell5,000.0030.96154,800.001,088,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,088,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-08-20Cedric FrancoisChief Executive OfficerSell3,457.0030.00103,710.001,093,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-08-18Cedric FrancoisChief Executive OfficerSell1,543.0030.0046,290.001,096,536.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-07-15Cedric FrancoisChief Executive OfficerSell5,000.0032.12160,600.001,098,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-06-15Cedric FrancoisChief Executive OfficerSell5,000.0030.21151,050.001,103,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-05-15Cedric FrancoisChief Executive OfficerSell5,000.0029.92149,600.001,108,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-04-15Cedric FrancoisChief Executive OfficerSell5,000.0029.77148,850.001,113,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-02-10LUKAS SCHEIBLEROfficerBuy9,375.0012,310.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-10-07Victoria L. BrownProgram Team LeadBuy12,000.0018.98227,760.0015,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10Timothy Eugene SullivanChief Financial OfficerBuy11,688.0023,387.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-10Nicole D PerryVice President - FinanceBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-10Ahmad SadrOfficerBuy2,725.002,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-11-02Federico GrossiCHIEF MEDICAL OFFICERSell600.0031.0918,654.0027,725.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-10-01Federico GrossiOfficerSell600.0030.2218,132.0028,325.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-09-01Federico GrossiOfficerSell600.0031.5818,948.0028,925.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-08-03Federico GrossiOfficerSell600.0026.2815,768.0029,525.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-07-01Federico GrossiOfficerSell850.0032.4327,565.5030,125.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-06-15Federico GrossiOfficerSell856.0030.2125,859.7630,975.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-02-10Federico GrossiOfficerBuy9,375.0031,831.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-10David O. WatsonGeneral CounselSell5,000.0044.50222,500.0035,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-10-07Victoria L. BrownProgram Team LeadSell12,000.0035.00420,000.003,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10David O. WatsonGeneral CounselBuy6,375.0040,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-10David O. WatsonGeneral CounselBuy7,505.002.6720,038.3542,922.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-05-08PAUL R. FONTEYNEDirectorBuy5,000.0031.81159,034.005,000.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-02-10Lucia CelonaOfficerBuy5,213.005,213.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-14Alec MachielsDirectorSell2,500.0042.35105,875.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorSell2,500.0030.2175,525.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-07Alec MachielsDirectorSell7,500.0035.00262,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-15Alec MachielsDirectorSell2,500.0035.0087,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-02-14Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-10-07Alec MachielsDirectorBuy7,500.002.6720,025.00677,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-02-10Thomas A. LacknerOfficerBuy2,725.007,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-10Pascal DeschateletsChief Operating OfficerBuy9,375.00891,118.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-10Adam J. TownsendOfficerBuy9,375.009,375.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerSell52,075.0042.802,228,966.23946,874.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerBuy117,206.002.14250,820.84998,949.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm